With a market capitalization (market cap) of $1.96B — a measure of how much the company is worth — Damora Therapeutics, Inc. is the 2124th most valuable company in Healthcare as of August 19, 2026. Shares trade at $31.80, up +2.28% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
Visit websiteAs of August 19, 2026, Damora Therapeutics, Inc. (DMRA) is worth $1.96B — this is its market capitalization, the total value of all its outstanding shares.
Damora Therapeutics, Inc.’s market cap is $1.96B, which ranks it #2124 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Damora Therapeutics, Inc. (DMRA) shares trade at $31.80, up 2.28% on the day, as of August 19, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025